Cyrielle Caussy1,2, Cynthia Hsu1, Min-Tzu Lo3, Amy Liu1, Ricki Bettencourt1, Veeral H Ajmera1, Shirin Bassirian1, Jonathan Hooker4, Ethan Sy4, Lisa Richards1, Nicholas Schork5, Bernd Schnabl1,6, David A Brenner1,6, Claude B Sirlin4, Chi-Hua Chen3, Rohit Loomba1,6,7. 1. NAFLD Research Center, Department of Medicine, La Jolla, California. 2. Université Lyon 1, Hospices Civils de Lyon, Lyon, France. 3. Department of Radiology, University of California at San Diego, La Jolla, California. 4. Liver Imaging Group, Department of Radiology, University of California at San Diego, La Jolla, California. 5. Human Biology, J. Craig Venter Institute, La Jolla, California. 6. Division of Gastroenterology, Department of Medicine, La Jolla, California. 7. Division of Epidemiology, Department of Family and Preventive Medicine, University of California at San Diego, La Jolla, California.
Abstract
Previous studies have shown that gut-microbiome is associated with nonalcoholic fatty liver disease (NAFLD). We aimed to examine if serum metabolites, especially those derived from the gut-microbiome, have a shared gene-effect with hepatic steatosis and fibrosis. This is a cross-sectional analysis of a prospective discovery cohort including 156 well-characterized twins and families with untargeted metabolome profiling assessment. Hepatic steatosis was assessed using magnetic-resonance-imaging proton-density-fat-fraction (MRI-PDFF) and fibrosis using MR-elastography (MRE). A twin additive genetics and unique environment effects (AE) model was used to estimate the shared gene-effect between metabolites and hepatic steatosis and fibrosis. The findings were validated in an independent prospective validation cohort of 156 participants with biopsy-proven NAFLD including shotgun metagenomics sequencing assessment in a subgroup of the cohort. In the discovery cohort, 56 metabolites including 6 microbial metabolites had a significant shared gene-effect with both hepatic steatosis and fibrosis after adjustment for age, sex and ethnicity. In the validation cohort, 6 metabolites were associated with advanced fibrosis. Among them, only one microbial metabolite, 3-(4-hydroxyphenyl)lactate, remained consistent and statistically significantly associated with liver fibrosis in the discovery and validation cohort (fold-change of higher-MRE versus lower-MRE: 1.78, P < 0.001 and of advanced versus no advanced fibrosis: 1.26, P = 0.037, respectively). The share genetic determination of 3-(4-hydroxyphenyl)lactate with hepatic steatosis was RG :0.57,95%CI:0.27-0.80, P < 0.001 and with fibrosis was RG :0.54,95%CI:0.036-1, P = 0.036. Pathway reconstruction linked 3-(4-hydroxyphenyl)lactate to several human gut-microbiome species. In the validation cohort, 3-(4-hydroxyphenyl)lactate was significantly correlated with the abundance of several gut-microbiome species, belonging only to Firmicutes, Bacteroidetes and Proteobacteria phyla, previously reported as associated with advanced fibrosis. Conclusion: This proof of concept study provides evidence of a link between the gut-microbiome and 3-(4-hydroxyphenyl)lactate that shares gene-effect with hepatic steatosis and fibrosis. (Hepatology 2018).
Previous studies have shown that gut-microbiome is associated with nonalcoholic fatty liver disease (NAFLD). We aimed to examine if serum metabolites, especially those derived from the gut-microbiome, have a shared gene-effect with hepatic steatosis and fibrosis. This is a cross-sectional analysis of a prospective discovery cohort including 156 well-characterized twins and families with untargeted metabolome profiling assessment. Hepatic steatosis was assessed using magnetic-resonance-imaging proton-density-fat-fraction (MRI-PDFF) and fibrosis using MR-elastography (MRE). A twin additive genetics and unique environment effects (AE) model was used to estimate the shared gene-effect between metabolites and hepatic steatosis and fibrosis. The findings were validated in an independent prospective validation cohort of 156 participants with biopsy-proven NAFLD including shotgun metagenomics sequencing assessment in a subgroup of the cohort. In the discovery cohort, 56 metabolites including 6 microbial metabolites had a significant shared gene-effect with both hepatic steatosis and fibrosis after adjustment for age, sex and ethnicity. In the validation cohort, 6 metabolites were associated with advanced fibrosis. Among them, only one microbial metabolite, 3-(4-hydroxyphenyl)lactate, remained consistent and statistically significantly associated with liver fibrosis in the discovery and validation cohort (fold-change of higher-MRE versus lower-MRE: 1.78, P < 0.001 and of advanced versus no advanced fibrosis: 1.26, P = 0.037, respectively). The share genetic determination of 3-(4-hydroxyphenyl)lactate with hepatic steatosis was RG :0.57,95%CI:0.27-0.80, P < 0.001 and with fibrosis was RG :0.54,95%CI:0.036-1, P = 0.036. Pathway reconstruction linked 3-(4-hydroxyphenyl)lactate to several humangut-microbiome species. In the validation cohort, 3-(4-hydroxyphenyl)lactate was significantly correlated with the abundance of several gut-microbiome species, belonging only to Firmicutes, Bacteroidetes and Proteobacteria phyla, previously reported as associated with advanced fibrosis. Conclusion: This proof of concept study provides evidence of a link between the gut-microbiome and 3-(4-hydroxyphenyl)lactate that shares gene-effect with hepatic steatosis and fibrosis. (Hepatology 2018).
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass Journal: Hepatology Date: 2012-07-26 Impact factor: 17.425
Authors: Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson Journal: Cell Metab Date: 2017-05-02 Impact factor: 27.287
Authors: Harmen H M Draisma; Marian Beekman; René Pool; Gert-Jan B van Ommen; Jerzy Adamski; Cornelia Prehn; Anika A M Vaarhorst; Anton J M de Craen; Gonneke Willemsen; P Eline Slagboom; Dorret I Boomsma Journal: Twin Res Hum Genet Date: 2013-08-28 Impact factor: 1.587
Authors: George Nicholson; Mattias Rantalainen; Anthony D Maher; Jia V Li; Daniel Malmodin; Kourosh R Ahmadi; Johan H Faber; Ingileif B Hallgrímsdóttir; Amy Barrett; Henrik Toft; Maria Krestyaninova; Juris Viksna; Sudeshna Guha Neogi; Marc-Emmanuel Dumas; Ugis Sarkans; Bernard W Silverman; Peter Donnelly; Jeremy K Nicholson; Maxine Allen; Krina T Zondervan; John C Lindon; Tim D Spector; Mark I McCarthy; Elaine Holmes; Dorrit Baunsgaard; Chris C Holmes Journal: Mol Syst Biol Date: 2011-08-30 Impact factor: 11.429
Authors: Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell Journal: Nature Date: 2012-02-01 Impact factor: 49.962
Authors: Jari E Kaikkonen; Peter Würtz; Emmi Suomela; Miia Lehtovirta; Antti J Kangas; Antti Jula; Vera Mikkilä; Jorma S A Viikari; Markus Juonala; Tapani Rönnemaa; Nina Hutri-Kähönen; Mika Kähönen; Terho Lehtimäki; Pasi Soininen; Mika Ala-Korpela; Olli T Raitakari Journal: Hepatology Date: 2016-12-24 Impact factor: 17.425
Authors: Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba Journal: Gut Date: 2018-12-19 Impact factor: 23.059
Authors: Kelly E Mercer; Laxmi Yeruva; Lindsay Pack; James L Graham; Kimber L Stanhope; Sree V Chintapalli; Umesh D Wankhade; Kartik Shankar; Peter J Havel; Sean H Adams; Brian D Piccolo Journal: Am J Physiol Gastrointest Liver Physiol Date: 2020-06-08 Impact factor: 4.052